Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy

  • Fernández-Juárez, Gema|||0000-0001-6641-7763
  • Rojas-Rivera, Jorge E.|||0000-0003-2730-6328
  • Logt, Anne-Els van de
  • Justino, Joana
  • Sevillano Prieto, Angel Manuel|||0000-0001-9063-7037
  • Caravaca-Fontan, Fernando|||0000-0002-5830-9663
  • Ávila, Ana
  • Rabasco, Cristina
  • Cabello, Virginia
  • Varela, Alfonso
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
  • Martín-Reyes, Guillermo
  • Goicoechea, Marian|||0000-0002-7614-0830
  • Quintana, Luis F.|||0000-0001-7582-8476
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • Gómez-Martino, Juan Ramón
  • Cao, Mercedes
  • Rodríguez-Moreno, Antolina
  • Rivas, Begoña|||0000-0002-5886-9943
  • Galeano Alvarez, Cristina|||0000-0003-2785-8886
  • Bonet Sol, Josep
  • Romera, Ana
  • Shabaka, Amir|||0000-0001-7039-4701
  • Plaisier, Emmanuelle
  • Espinosa, Mario
  • Egido de los Rios, Jesus
  • Segarra-Medrano, Alfonso
  • Lambeau, Gérard
  • Ronco, Pierre|||0000-0002-0280-6900
  • Wetzels, Jack
  • Praga, Manuel|||0000-0001-9270-1071
  • Caravaca-Fontan, Fernando|||0000-0002-5830-9663
  • Trujillo, Hernando
  • Gutiérrez, Eduardo
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Verdalles, Úrsula
  • Segarra, Alfons
  • Perea, Lara
  • Valera, Ildefonso
  • Martín, Mónica
  • Pérez Valdivia, Miguel Angel
  • Blasco, Miquel Angel
  • López Muñiz, Andrés
  • Malek, Tamara
  • DaSilva Santos, Iara|||0000-0001-8203-6135
  • Bonet, Jordi
  • Navarro Diaz, Maruja Isabel|||0000-0003-3001-0595
  • Huerta, Ana|||0000-0003-3342-7628
  • Rodríguez-Paternina, Ezequiel
  • Vigil, Ana
  • Alcázar Arroyo, Roberto|||0000-0002-7433-3479
  • Paraíso, Vicente
  • Barrio, Vicente
  • Hofstra, Julia M.
A cyclical corticosteroid-cyclophosphamide regimen is recommended for patients with primary membranous nephropathy at high risk of progression. We hypothesized that sequential therapy with tacrolimus and rituximab is superior to cyclical alternating treatment with corticosteroids and cyclophosphamide in inducing persistent remission in these patients. This was tested in a randomized, open-label controlled trial of 86 patients with primary membranous nephropathy and persistent nephrotic syndrome after six-months observation and assigned 43 each to receive six-month cyclical treatment with corticosteroid and cyclophosphamide or sequential treatment with tacrolimus (full-dose for six months and tapering for another three months) and rituximab (one gram at month six). The primary outcome was complete or partial remission of nephrotic syndrome at 24 months. This composite outcome occurred in 36 patients (83.7%) in the corticosteroid-cyclophosphamide group and in 25 patients (58.1%) in the tacrolimus-rituximab group (relative risk 1.44; 95% confidence interval 1.08 to 1.92). Complete remission at 24 months occurred in 26 patients (60%) in the corticosteroid-cyclophosphamide group and in 11 patients (26%) in the tacrolimus-rituximab group (2.36; 1.34 to 4.16). Anti-PLA2R titers showed a significant decrease in both groups but the proportion of anti-PLA2R-positive patients who achieved immunological response (depletion of anti-PLA2R antibodies) was significantly higher at three and six months in the corticosteroid-cyclophosphamide group (77% and 92%, respectively), as compared to the tacrolimus-rituximab group (45% and 70%, respectively). Relapses occurred in one patient in the corticosteroid-cyclophosphamide group, and three patients in the tacrolimus-rituximab group. Serious adverse events were similar in both groups. Thus, treatment with corticosteroid-cyclophosphamide induced remission in a significantly greater number of patients with primary membranous nephropathy than tacrolimus-rituximab.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy

  • Caravaca-Fontan, Fernando|||0000-0002-5830-9663
  • Rivero, Marta
  • Cavero Escribano, Teresa|||0000-0001-5187-9906
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
  • Cabello, Virginia
  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Quintana, Luis F.|||0000-0001-7582-8476
  • Marco Rusiñol, Helena|||0000-0002-7229-8729
  • Barros, Xoana|||0000-0001-9690-9769
  • Ramos Terrades, Natalia|||0000-0001-9832-326X
  • Rodríguez-Mendiola, Nuria
  • Cruz, Sonia
  • Fernández-Juárez, Gema|||0000-0001-6641-7763
  • Rodríguez Barba, Adela|||0000-0003-4382-3085
  • Pérez de José, Ana
  • Rabasco, Cristina
  • Rodado, Raquel
  • Fernández, Loreto
  • Pérez-Gómez, Maria Vanessa|||0000-0003-4558-5236
  • Ávila, Ana
  • Bravo, Luis
  • Espinosa, Natalia
  • Allende, Natalia|||0000-0001-9857-793X
  • Sánchez de la Nieta, María Dolores
  • Rodríguez García, Eva
  • Olea, Teresa
  • Melgosa, Marta|||0000-0001-6236-414X
  • Huerta, Ana|||0000-0003-3342-7628
  • Miquel, Rosa
  • Mon, Carmen
  • Fraga Rodriguez, Gloria Maria|||0000-0002-7682-1396
  • De Lorenzo, Alberto
  • Draibe, Juliana
  • González, Fayna
  • Shabaka, Amir|||0000-0001-7039-4701
  • López-Rubio, Maria Esperanza
  • Fenollosa, María Ángeles
  • Martín-Penagos, Luis
  • Da Silva, Iara
  • Alonso Titos, Juana
  • Rodríguez de Córdoba, Santiago|||0000-0001-6401-1874
  • Goicoechea de Jorge, Elena|||0000-0002-4978-2483
  • Praga, Manuel|||0000-0001-9270-1071
Background: C3 glomerulopathy is a rare and heterogeneous complement-driven disease. It is often challenging to accurately predict in clinical practice the individual kidney prognosis at baseline. We herein sought to develop and validate a prognostic nomogram to predict long-Term kidney survival. Methods: We conducted a retrospective, multicenter observational cohort study in 35 nephrology departments belonging to the Spanish Group for the Study of Glomerular Diseases. The dataset was randomly divided into a training group (n = 87) and a validation group (n = 28). The least absolute shrinkage and selection operator (LASSO) regression was used to screen the main predictors of kidney outcome and to build the nomogram. The accuracy of the nomogram was assessed by discrimination and risk calibration in the training and validation sets. Results: The study group comprised 115 patients, of whom 46 (40%) reached kidney failure in a median follow-up of 49 months (range 24-112). No significant differences were observed in baseline estimated glomerular filtration rate (eGFR), proteinuria or total chronicity score of kidney biopsies, between patients in the training versus those in the validation set. The selected variables by LASSO were eGFR, proteinuria and total chronicity score. Based on a Cox model, a nomogram was developed for the prediction of kidney survival at 1, 2, 5 and 10 years from diagnosis. The C-index of the nomogram was 0.860 (95% confidence interval 0.834-0.887) and calibration plots showed optimal agreement between predicted and observed outcomes. Conclusions: We constructed and validated a practical nomogram with good discrimination and calibration to predict the risk of kidney failure in C3 glomerulopathy patients at 1, 2, 5 and 10 years.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy

  • Caravaca-Fontan, Fernando|||0000-0002-5830-9663
  • Cavero Escribano, Teresa|||0000-0001-5187-9906
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
  • Cabello, Virginia
  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Quintana, Luis F.|||0000-0001-7582-8476
  • Marco Rusiñol, Helena|||0000-0002-7229-8729
  • Barros, Xoana|||0000-0001-9690-9769
  • Ramos Terrades, Natalia|||0000-0001-9832-326X
  • Rodríguez-Mendiola, Nuria
  • Cruz, Sonia
  • Fernández-Juárez, Gema|||0000-0001-6641-7763
  • Rodríguez, Adela|||0000-0002-4899-6607
  • Pérez de José, Ana
  • Rabasco, Cristina
  • Rodado, Raquel
  • Fernández, Loreto
  • Pérez-Gómez, Vanessa
  • Ávila, Ana
  • Bravo, Luis
  • Espinosa, Natalia
  • Allende, Natalia|||0000-0001-9857-793X
  • Sánchez de la Nieta, María Dolores
  • Rodríguez García, Eva
  • Rivas, Begoña|||0000-0002-5886-9943
  • Melgosa, Marta|||0000-0001-6236-414X
  • Huerta, Ana|||0000-0003-3342-7628
  • Miquel, Rosa
  • Mon, Carmen
  • Fraga Rodriguez, Gloria Maria|||0000-0002-7682-1396
  • De Lorenzo, Alberto
  • Draibe, Juliana
  • González, Fayna
  • Shabaka, Amir|||0000-0001-7039-4701
  • López-Rubio, Maria Esperanza
  • Fenollosa, María Ángeles
  • Martín-Penagos, Luis
  • Da Silva, Iara
  • Titos, Juana Alonso
  • Rodríguez de Córdoba, Santiago|||0000-0001-6401-1874
  • Goicoechea de Jorge, Elena|||0000-0002-4978-2483
  • Praga, Manuel|||0000-0001-9270-1071
C3 glomerulopathy is a rare kidney disease, which makes it difficult to collect large cohorts of patients to better understand its variability. The aims of this study were to describe the clinical profiles and patterns of progression of kidney disease. This was a retrospective, observational cohort study. Patients diagnosed with C3 glomerulopathy between 1995 and 2020 were enrolled. Study population was divided into clinical profiles by combining the following predictors: eGFR under/above 30 ml/min per 1.73 m 2, proteinuria under/above 3.5 g/d, and histologic chronicity score under/above 4. The change in eGFR and proteinuria over time was evaluated in a subgroup with consecutive measurements of eGFR and proteinuria. One hundred and fifteen patients with a median age of 30 years (interquartile range 19-50) were included. Patients were divided into eight clinical profiles. Kidney survival was significantly higher in patients with a chronicity score <4 and proteinuria <3.5 g/d, both in those presenting with an eGFR under/above 30 ml/min per 1.73 m 2. The median eGFR slope of patients who reached kidney failure was -6.5 ml/min per 1.73 m 2 per year (interquartile range -1.6 to -17). Patients who showed a reduction in proteinuria over time did not reach kidney failure. On the basis of the rate of eGFR decline, patients were classified as faster eGFR decline (≥5 ml/min per 1.73 m 2 per year), slower (<5 ml/min per 1.73 m 2 per year), and those without decline. A faster eGFR decline was associated with higher probability of kidney failure. Kidney survival is significantly higher in patients with a chronicity score <4 and proteinuria <3.5 g/d regardless of baseline eGFR, and a faster rate of decline in eGFR is associated with higher probability of kidney failure.